Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

Precision DNA editing gene therapy achieves deep remissions in aggressive leukemia previously considered incurable.

At a Food and Drug Administration cell and gene therapy (CGT) roundtable last June, most speakers pushed for the agency to ...

Under the agreement, participating states will receive “discounts and rebates” from the drugmakers if the treatments don’t ...

"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are common-sense reforms that will address the unique characteristics of cell and ...

NHS Scotland has approved a one-time CRISPR gene therapy for severe sickle cell disease, offering durable reduction in vaso-occlusive crises for eligible patients.

GEN’s first virtual event of 2026—we present a group of outstanding researchers and thought-leaders to discuss the latest advances and challenges in delivering genetic therapies.

The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...

Medicaid is doing a novel payment system for the new, promising and expensive sickle cell treatment. It may become a model ...

Key market opportunities in cell and gene therapy include tracking investment trends, analyzing key deals, and staying updated with scientific developments and market forecasts. The publication is ...